Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma
详细信息 查看全文
- 作者：Emilie Chalayer ; MD ; PhDa ; emilie.chalayer@chu-st-etienne.fr" class="auth_mail" title="E-mail the corresponding author ; Auré ; lie Bourmaud ; MD ; PhDa ; b ; c ; aurelie.bourmaud@icloire.fr" class="auth_mail" title="E-mail the corresponding author ; Fabien Tinquautc ; Fabien.tinquaut@icloire.fr" class="auth_mail" title="E-mail the corresponding author ; Franck Chauvin ; MD ; PhDa ; b ; c ; franck.chauvin@icloire.fr" class="auth_mail" title="E-mail the corresponding author ; Bernard Tardy ; MD ; PhDa ; bernardtardy@yahoo.fr" class="auth_mail" title="E-mail the corresponding author
- 关键词：TE ; Venous thromboembolic events ; MM ; multiple myeloma ; IMiDs ; Immunomodulatory drugs ; LMWH ; low-molecular weight heparin ; QALYs ; quality-adjusted life years ; PE ; pulmonary embolism ; DVT ; deep venous thrombosis ; AT ; arterial thrombosis ; AMI ; acute myocardial infarction ; HRQoL ; health-related quality of life ; ICER ; incremental cost-effectiveness ratio
- 刊名：Thrombosis Research
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：145
- 期：Complete
- 页码：119-125
- 全文大小：450 K
文摘
- •
In newly diagnosed multiple myeloma, heparin is not better than low-dose aspirin to prevent thromboembolism.
- •
Low-molecular weight heparin strategy has the disadvantage of being more expensive than low-dose aspirin strategy.
- •
The used of low-dose aspirin provided benefit for quality of life.
- •
Societies guidelines recommending thromboprophylaxis in multiple myeloma should be revisited in the light of these findings